Compare Stocks: NRC, SDGR, CERT, and GDRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$8.13 -1.8%	$7.59	$4.45 ▼ $13.88	$1.26B	1.4	2.61 million shs	2.13 million shs
GDRX GoodRx	$3.53 +2.3%	$3.27	$1.77 ▼ $5.81	$1.18B	1.59	1.89 million shs	1.46 million shs
NRC National Research	$21.25 +6.2%	$21.27	$11.01 ▼ $23.68	$455.15M	0.35	121,150 shs	168,008 shs
SDGR Schrodinger	$20.71 -0.8%	$17.29	$10.94 ▼ $23.02	$1.54B	1.69	1.17 million shs	771,476 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	-1.81%	-3.33%	+4.23%	+51.40%	-22.57%
GDRX GoodRx	+2.32%	+0.57%	+5.69%	+33.21%	-17.72%
NRC National Research	+6.20%	-3.45%	+8.47%	+11.02%	+44.26%
SDGR Schrodinger	-0.81%	+1.47%	+32.33%	+44.02%	+7.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$8.13 -1.8%	$7.59	$4.45 ▼ $13.88	$1.26B	1.4	2.61 million shs	2.13 million shs
GDRX GoodRx	$3.53 +2.3%	$3.27	$1.77 ▼ $5.81	$1.18B	1.59	1.89 million shs	1.46 million shs
NRC National Research	$21.25 +6.2%	$21.27	$11.01 ▼ $23.68	$455.15M	0.35	121,150 shs	168,008 shs
SDGR Schrodinger	$20.71 -0.8%	$17.29	$10.94 ▼ $23.02	$1.54B	1.69	1.17 million shs	771,476 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	-1.81%	-3.33%	+4.23%	+51.40%	-22.57%
GDRX GoodRx	+2.32%	+0.57%	+5.69%	+33.21%	-17.72%
NRC National Research	+6.20%	-3.45%	+8.47%	+11.02%	+44.26%
SDGR Schrodinger	-0.81%	+1.47%	+32.33%	+44.02%	+7.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERT Certara	2.42	Hold	$8.28	1.82% Upside
GDRX GoodRx	2.08	Hold	$4.23	19.75% Upside
NRC National Research	2.50	Moderate Buy	$26.00	22.35% Upside
SDGR Schrodinger	2.29	Hold	$20.50	-1.01% Downside

Current Analyst Ratings Breakdown

Latest NRC, SDGR, CERT, and GDRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	NRC National Research	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/20/2026	GDRX GoodRx	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$3.00 ➝ $4.00
8/14/2026	SDGR Schrodinger	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00 ➝ $19.00
8/14/2026	SDGR Schrodinger	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00 ➝ $19.00
8/13/2026	GDRX GoodRx	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$2.50 ➝ $3.75
8/12/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	GDRX GoodRx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
8/11/2026	GDRX GoodRx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
8/7/2026	GDRX GoodRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/7/2026	GDRX GoodRx	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$4.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERT Certara	$418.84M	2.96	$0.74 per share	10.94	$6.34 per share	1.28
GDRX GoodRx	$796.85M	1.52	$0.41 per share	8.62	$1.89 per share	1.87
NRC National Research	$137.39M	3.52	$1.34 per share	15.91	$0.29 per share	73.28
SDGR Schrodinger	$255.87M	5.97	N/A	N/A	$4.46 per share	4.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERT Certara	-$1.60M	-$0.45	N/A	29.04	N/A	-16.75%	3.86%	2.65%	11/5/2026 (Estimated)
GDRX GoodRx	$30.44M	$0.04	88.27	17.65	1.72	2.07%	7.22%	2.53%	11/3/2026 (Estimated)
NRC National Research	$11.60M	$0.25	85.00	N/A	N/A	4.18%	164.26%	14.67%	10/26/2026 (Estimated)
SDGR Schrodinger	-$103.26M	-$0.74	N/A	N/A	N/A	-20.98%	-16.37%	-8.19%	11/4/2026 (Estimated)

Latest NRC, SDGR, CERT, and GDRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	GDRX GoodRx	$0.0797	$0.08	+$0.0003	$0.02	$193.23 million	$200.41 million
8/5/2026	Q2 2026	SDGR Schrodinger	-$0.4145	$0.08	+$0.4945	$0.08	$47.19 million	$58.89 million
8/4/2026	Q2 2026	CERT Certara	$0.0893	$0.08	-$0.0093	-$0.36	$98.09 million	$93.27 million
7/28/2026	Q2 2026	NRC National Research	-$0.15	$0.31	+$0.46	-$0.15	$34.90 million	$35.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERT Certara	N/A	N/A	N/A	N/A	N/A
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
NRC National Research	$0.64	3.01%	+19.88%	256.00%	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Latest NRC, SDGR, CERT, and GDRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/15/2026	NRC National Research	quarterly	$0.16	2.86%	9/25/2026	9/25/2026	10/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERT Certara	0.30	2.55	2.55
GDRX GoodRx	0.74	1.38	1.38
NRC National Research	13.13	0.65	0.65
SDGR Schrodinger	N/A	2.71	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERT Certara	73.96%
GDRX GoodRx	63.77%
NRC National Research	47.26%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
CERT Certara	1.08%
GDRX GoodRx	5.87%
NRC National Research	9.20%
SDGR Schrodinger	10.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERT Certara	1,576	152.54 million	150.89 million	Optionable
GDRX GoodRx	950	342.57 million	322.47 million	Optionable
NRC National Research	490	22.75 million	20.65 million	Optionable
SDGR Schrodinger	790	73.82 million	66.37 million	Optionable

NRC, SDGR, CERT, and GDRX Headlines

Recent News About These Companies

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 438,798 Shares of Schrodinger, Inc. $SDGR

2 hours ago | marketbeat.com

Schrodinger (NASDAQ:SDGR) Shares Down 4.5% - Here's Why

September 2 at 12:39 PM | marketbeat.com

Schrodinger (NASDAQ:SDGR) Trading 4.6% Higher - Should You Buy?

September 1 at 3:00 PM | marketbeat.com

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

September 1 at 8:30 AM | businesswire.com

Beacon Pointe Advisors LLC Takes Position in Schrodinger, Inc. $SDGR

September 1 at 3:20 AM | marketbeat.com

Deutsche Bank AG Purchases Shares of 62,368 Schrodinger, Inc. $SDGR

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Makes New $3.18 Million Investment in Schrodinger, Inc. $SDGR

August 29, 2026 | marketbeat.com

BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGR

August 29, 2026 | marketbeat.com

Algert Global LLC Trims Stake in Schrodinger, Inc. $SDGR

August 28, 2026 | marketbeat.com

71,397 Shares in Schrodinger, Inc. $SDGR Bought by Ieq Capital LLC

August 27, 2026 | marketbeat.com

Schrödinger, Inc. (SDGR) Stock Price, News, Quote & History - Yahoo Finance

August 25, 2026 | finance.yahoo.com

Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Hold" by Analysts

August 25, 2026 | americanbankingnews.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Hold" from Analysts

August 25, 2026 | marketbeat.com

Schrödinger: The Software Business Is Stronger Than It Looks

August 22, 2026 | seekingalpha.com

Tejara Capital Ltd Takes $4.55 Million Position in Schrodinger, Inc. $SDGR

August 21, 2026 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Trading 10.4% Higher - What's Next?

August 19, 2026 | marketbeat.com

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

August 17, 2026 | zacks.com

Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100

August 14, 2026 | gurufocus.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 14, 2026 | businesswire.com

Schrödinger (SDGR) Q2 2026 Earnings Call Transcript

August 13, 2026 | fool.com

Quantinno Capital Management LP Buys Shares of 174,095 Schrodinger, Inc. $SDGR

August 12, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NRC, SDGR, CERT, and GDRX Company Descriptions

Certara NASDAQ:CERT

$8.13 -0.15 (-1.81%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$8.12 -0.01 (-0.06%)

As of 06:35 AM Eastern

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

GoodRx NASDAQ:GDRX

$3.53 +0.08 (+2.32%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$3.54 +0.01 (+0.28%)

As of 07:18 AM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

National Research NASDAQ:NRC

$21.25 +1.24 (+6.20%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$21.26 +0.02 (+0.07%)

As of 06:45 AM Eastern

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Schrodinger NASDAQ:SDGR

$20.71 -0.17 (-0.81%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$20.60 -0.11 (-0.53%)

As of 07:11 AM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRC, SDGR, CERT, and GDRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRC, SDGR, CERT, and GDRX Earnings

Compare Dividends

Latest NRC, SDGR, CERT, and GDRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRC, SDGR, CERT, and GDRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NRC, SDGR, CERT, and GDRX Company Descriptions

Certara NASDAQ:CERT

GoodRx NASDAQ:GDRX

National Research NASDAQ:NRC

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools